原始出處紀錄
決策級主要結果 (Topline)
Quince Therapeutics：LAM-001 針對 PH-ILD 的 2b 期數據預計於 2028 年第一季公布
收購 Orphai Therapeutics 後，Quince 的管線新增 LAM-001。一項針對 PH-ILD 的 75 人 2b 期試驗正在進行中，初步結果預計於 2028 年第一季公布。另一項 BOS 的 2 期試驗已完成招募，結果預計於 2027 年第一季公布。
關鍵事實
來源摘錄
EX-99.4 3 d163930dex994.htm EX-99.4 EX-99.4 Exhibit 99.4 BUSINESS Our Company We are a clinical-stage biopharmaceutical company developing a novel disease modifying therapeutic to address the significant unmet medical need associated with pulmonary disorders with few, if any, treatment options available. On May 18, 2026, we completed the acquisition of Orphai Therapeutics, a clinical-stage biopharmaceutical company developing therapies to treat serious, underserved pulmonary disorders. The acquisition brought into our pipeline Orphai’s lead asset, LAM-001, a proprietary investigational inhaled dry powder formulation of rapamycin whose differentiated characteristics may permit treatment of conditions associated with dysfunctional mammalian target of rapamycin (“mTOR”) activity that cann